Hayashida, Tetsu

写真a

Affiliation

School of Medicine, Department of Surgery (Breast Surgery) (Shinanomachi)

Position

Professor

Related Websites

External Links
Page Top ▲

Career 【 Display / hide 】

  • 1998.05
    -
    Present

    慶應義塾大学医学部, 外科学, 研修医

  • 2000.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手（専修医）

  • 2001.05
    -
    Present

    慶應義塾大学医学部, 外科学, 助手

  • 2005.05
    -
    2008.05

    Harvard medical school & Massachusetts General Hospital, Department of Surgery, Cancer center, Research fellow

  • 2008.06
    -
    Present

    慶應義塾大学医学部, 外科学, 助教

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1992.04
    -
    1998.03

    Keio University, 医学部

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, 慶應義塾大学, 2007

    ドメイン内插入融合蛋白(FGF-RNase fused protein)による3次元培養モデルにおける血管新生阻害効果

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 医師免許, 1998.05

  • 日本外科学会専門医, 2004.12

  • 日本がん治療認定医機構癌治療認定医, 2014.04

  • 日本乳癌学会認定位, 2014.04

  • 日本乳がん検診精度管理中央機構　検診マンモグラフィー読影認定医(A), 2015.06

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / General surgery and pediatric surgery

Page Top ▲

Research Keywords 【 Display / hide 】

  • Breast cancer

  • Breast surgery

Page Top ▲
 

Books 【 Display / hide 】

  • Chemoprevention for Breast Cancer

    Watanuki R., Nagayama A., Hayashida T., Kitagawa Y., Hereditary Breast and Ovarian Cancer Molecular Mechanism and Clinical Practice, 2021.01

    　View Summary

    Cancer chemoprevention is defined as the use of natural, synthetic, or biochemical agents to reverse, suppress, or prevent carcinogenic processes in neoplastic diseases. Although the precise mechanisms that promote breast cancer are not fully understood, several recent clinical trials suggest that chemoprevention is a rational and attractive strategy for selected high-risk populations in a prophylactic setting. Conventionally, endocrine interventions using selective estrogen receptor modulators and aromatase inhibitors have already been applied clinically in high-risk populations. In particular, the chemoprevention approach for BRCA germline mutation carriers is drawing attention as an alternative option to invasive prophylactic mastectomy. Although the evidence from prospective clinical studies was limited, this review aims to provide an up-to-date overview of the biological mechanisms and the efficacy of various chemopreventive agents, including new promising candidates that target BRCA deficiency, and discuss future challenges and prospects for breast cancer chemoprevention.

Page Top ▲

Papers 【 Display / hide 】

  • 増大号 全領域をコンプリート!　超進化!AI時代の臨床検査 各論 3章　生理学的検査 乳房超音波検査

    亀山 友恵, 林田 哲

    検査と技術 (株式会社医学書院)  53 ( 8 ) 912 - 915 2025.08

    Joint Work,  ISSN  03012611

  • The Future of Breast Cancer Diagnosis in Japan with AI and Ultrasonography

    Fujioka Tomoyuki, Tsukada Jitsuro, Hayashida Tetsu, Yamaga Emi, Tsukada Hiroko, Kubota Kazunori, Tateishi Ukihide

    JMA Journal (Japan Medical Association / The Japanese Associaiton of Medical Sciences)  8 ( 1 ) 91 - 101 2025.01

    Joint Work,  ISSN  2433328X

    　View Summary

    <p>In Japan, mammography is commonly used for breast cancer screening. However, the mortality rate has not decreased, possibly due to the low screening uptake and the high prevalence of dense breast tissue among Japanese women, which reduces mammography's effectiveness. A recent prospective study in Japan, J-START, demonstrated that combining mammography with ultrasonography increases detection rates and reduces the incidence of interval cancers, highlighting the significance of ultrasound examinations.</p><p>Artificial Intelligence (AI) technologies, particularly in machine learning and deep learning, offer promising solutions to enhance the accuracy and efficiency of breast ultrasound diagnostics. This review explores AI's current capabilities in breast ultrasound imaging, emphasizing key advancements in breast lesion detection and diagnosis. Additionally, we introduce AI-based breast ultrasound diagnostic support programs approved by the Pharmaceuticals and Medical Devices Agency, which include programs for detecting lesion candidate regions and diagnosing the necessity of further examination based on detected lesion candidates. These AI tools are expected to improve diagnostic accuracy and efficiency.</p><p>While AI holds significant promise, several challenges remain. It is essential for physicians to oversee its use responsibly, as there are concerns regarding patient acceptance and environmental impact. This review underscores the revolutionary potential of AI in breast cancer diagnostics and emphasizes the importance of ongoing research and development to overcome existing limitations.</p>

  • A genome-wide CRISPR/Cas9 knockout screen identifies SEMA3F gene for resistance to cyclin-dependent kinase 4 and 6 inhibitors in breast cancer

    Kawai Y., Nagayama A., Miyao K., Takeuchi M., Yokoe T., Kameyama T., Wang X., Seki T., Takahashi M., Hayashida T., Kitagawa Y.

    Breast Cancer 32 ( 1 ) 120 - 131 2025.01

    Joint Work,  ISSN  13406868

    　View Summary

    Background: Palbociclib is a cell-cycle targeted small molecule agent used as one of the standards of care in combination with endocrine therapy for patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Although several gene alterations such as loss of Rb gene and amplification of p16 gene are known to be conventional resistance mechanisms to cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, the comprehensive landscape of resistance is not yet fully elucidated. The purpose of this study is to identify the novel resistant genes to the CDK4/6 inhibitors in HR-positive HER2-negative breast cancer. Methods: The whole genome knockout screen using CRISPR/Cas9 genome editing was conducted in MCF7 to identify resistant genes to palbociclib. The candidate genes for resistance were selected by NGS analysis and GSEA analysis and validated by cell viability assay and mouse xenograft models. Results: We identified eight genes including RET, TIRAP, GNRH1, SEMA3F, SEMA5A, GATA4, NOD1, SSTR1 as candidate genes from the whole genome knockout screen. Among those, knockdown of SEMA3F by siRNA significantly and consistently increased the cell viability in the presence of CDK4/6 inhibitors in vitro and in vivo. Furthermore, the level of p-Rb was maintained in the palbociclib treated SEMA3F-downregulated cells, indicating that the resistance is driven by increased activity of cyclin kinases. Conclusion: Our observation provided the first evidence of SEMA3F as a regulator of sensitivity to CDK4/6 inhibitors in breast cancer. The detailed mechanisms of resistance deserve further functional studies to develop the better strategy to overcome resistance in CDK4/6 inhibitors.

  • AI for Imaging Diagnosis in Breast Cancer Screening

    Kataoka Masako, Fujioka Tomoyuki, Inoue Kenichi, Hayashida Tetsu, Suzuki Takashi

    Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening) (Japan Association of Breast Cancer Screening)  34 ( 1 ) 15 - 21 2025

    Joint Work,  ISSN  09180729

    　View Summary

    In breast cancer screening, AI-based computer-aided diagnosis (AI-CAD) software has been introduced into diagnostic imaging, mainly mammography (MG), with the expectation of improving sensitivity or efficiency in reading. Overseas evidence demonstrates that sensitivity and specificity of AI-CAD in diagnosing breast cancer is equivalent to those of human readers. Reducing the work load of screening by replacing one of the readers by AI-CAD has been attempted. On the other hand, pitfalls of AI-CAD include automation bias, and the fluctuation of performance by AI-CAD caused by biased training data. Furthermore, when incorporating AI into actual clinical practice, operational considerations—such as the specific conditions of each facility, feasibility of system implementation and cloud utilization, security measures, and determining who will reference the AI-CAD output and at what stage—must all be taken into account.
    In the midst of the transition, it is becoming indispensable to develop guidelines at the academic society level, establish quality assurance systems, and accumulate evidence to verify AI’s usefulness over the mid to long term.

  • Exploring Breast Cancer Risk Management in HBOC Patients: Image Surveillance Versus Risk-reducing Surgery

    Seki Tomoko, Kobayashi Yusuke, Masuda Kenta, Nakamura Kohei, Yamada Mamiko, Goto Yumiko, Misu Kumiko, Ono Ikumi, Nagayama Aiko, Hayashida Tetsu, Kitagawa Yuko

    The Keio Journal of Medicine (The Keio Journal of Medicine)  advpub ( 0 )  2025

    Joint Work,  ISSN  00229717

    　View Summary

    <p>In Japan, the rising incidence of hereditary breast and ovarian cancer syndrome (HBOC) follows partial insurance coverage introduced in 2020. Compared with the general population (~11% lifetime risk), individuals with HBOC face a significantly higher lifetime risk of breast cancer (48%–76%), often presenting at younger ages. <i>BRCA1</i> mutations are linked to triple-negative breast cancer, whereas <i>BRCA2</i> mutations typically result in luminal-type disease. Key risk management strategies include surveillance and prophylactic surgery. Annual magnetic resonance imaging and mammography are recommended at younger ages than in the general population, despite concerns regarding contrast agents, radiation exposure, and examination-related burdens. Although risk-reducing mastectomy lowers breast cancer risk by over 90%, it remains underutilized because of cosmetic and psychological considerations. Nipple-sparing or skin-sparing mastectomy combined with immediate or delayed reconstruction offers a balance between risk reduction and postoperative outcomes, although safety and procedure details still warrant careful evaluation. Managing the high breast cancer risk associated with HBOC requires ongoing efforts to refine current strategies while minimizing patient burden.</p>

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Correction: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry (Annals of Surgical Oncology, (2022), 29, 3, (1722-1734), 10.1245/s10434-021-10930-1)

    Esgueva A.J., Noordhoek I., Kranenbarg E.M.K., Espinosa-Bravo M., Mátrai Z., Zhygulin A., Irmejs A., Mavioso C., Meani F., González E., Özdemir M., Allweis T., Rogowski K., dos Santos C.R., Mora H., Ponzone R., Samorani D., van de Velde C., Audisio R.A., Rubio I.T., Hayashida T., Acosta-Marín V., Kiernan T., Negreiros I., Paulinelli R.R.R., Srivastava A., Imoto S.S., Di Micco R., Bonetti A., Kołacińska A., Sallam I., Weber W., Luna-Bureo R., Ioannidis O., El-Shinawi M.

    Annals of Surgical Oncology 29 ( 9 )  2022.09

    Joint Work,  ISSN  10689265

    　View Summary

    The following members of the INSPIRE collaborators group are missing from the original article: Tetsu Hayashida (Keio University School of Medicine, Japan), Victor Acosta-Marı´n (CECLINES, Venezuela), Tamara Kiernan (St. Helens Hospital, UK), Ida Negreiros (CUF Descobertas Hospital, Portugal), Regis RR Paulinelli (Hospital Araujo Jorge, Brazil), Anurag Srivastava (All India Institute of Medical Sciences, India), Shigeru S. Imoto (Kyorin University School of Medicine), Rosa Di Micco (Ospedale San Raffaele, Italy), Andrea Bonetti (Ospedale Mater Salutis, Italy), Agnieszka Kołacin´ska (Medical University of Lodz, Poland), Ibrahim Sallam (MISR Cancer Center, Egypt), Walter Weber (USB, Switzerland), Rogelio Luna-Bureo (Hospital de Santa Maria, Portugal), Orestis Ioannidis (Aristotle University of Thessaloniki, Greece), Mohamed El-Shinawi (Ain Shams University, Egypt).

  • 【いまだからこそ見直される乳房温存手術】傍乳輪wave-like incisionと全乳房皮下剥離を併用した整容性の高い乳房温存手術

    菊池 雅之, 林田 哲, 北川 雄光

    手術 (金原出版(株))  73 ( 12 ) 1659 - 1666 2019.11

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0037-4423

  • 【がん遺伝子パネル検査の現状と展望】クリニカルシークエンスの現状と未来

    山口 茂夫, 林田 哲, 北川 雄光

    乳癌の臨床 ((株)篠原出版新社)  34 ( 5 ) 385 - 393 2019.10

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work,  ISSN  0911-2251

  • MRI造影病変に対するVolume Navigation Systemの有用性の検討

    高橋 麻衣子, 関 朋子, 林田 哲, 北川 雄光

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   O51 - 2 2019.10

    Joint Work

  • 機械学習法を用いた唾液メタボローム解析による乳癌スクリーニング

    村田 健, 柳澤 貴子, 栗原 俊明, 太田 紗菜, 金子 未来, 榎本 文芽, 冨田 勝, 杉本 昌弘, 砂村 眞琴, 林田 哲, 北川 雄光, 神野 浩光

    日本癌治療学会学術集会抄録集 ((一社)日本癌治療学会)  57回   O52 - 3 2019.10

    Joint Work

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • 肝癌に対する凍結融解壊死療（Cryoablation）

    Akatsu Tomotaka, Wakabayashi Gou, Tanabe Minoru, Ueda Masakazu, Shimazu Motohide, Aiura Kouichi, Kawachi Shigeyuki, Yoshida Masashi, Takigawa Yutaka, Hashimoto Takeo, Matsuura Yoshifumi, Abe Yuuta, Kido Hiromu, Hayashida Tetsu, Yagi Hiroshi, Itou Yasuhiro, Miyata Ryouhei, Kitajima Masaki

    第26回慶應外科フォーラム総会, 

    2003.01
    , 

    Oral presentation (general)

  • 当科における肝細胞癌に対する生体部分肝移植

    Akatsu Tomotaka, Shimazu Motohide, Wakabayashi Gou, Tanabe Minoru, Hoshino Ken, Kawachi Shigeyuki, Yoshida Masashi, Watanabe Toshihiko, Shibutani Shintarou, Hashimoto Takeo, Takigawa Yutaka, Shimojima Naoki, Abe Yuuta, Kaneda Munehisa, Kido Hiromu, Shintani Tsunehiro, Hayashida Tetsu, Yagi Hiroshi, Akiyoshi Takurin, Itou Yasuhiro, Inoue Fumihiko, Miyata Ryouhei, Morikawa Yasuhide, Kitajima Masaki

    第26回慶應外科フォーラム総会, 

    2003.01
    , 

    Oral presentation (invited, special)

  • c-kit陽性GISTに対しメシル酸イマチニブが著効を認めた1症例

    Hayashida Tetsu, Ueda Masakazu, Kawachi Shigeyuki, Tanabe Minoru, Aiura Kouichi, Wakabayashi Gou, Ootani Yoshihide, Shimazu Motohide, Kubota Tetsurou, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

  • 非機能性膵内分泌腫瘍9例の検討

    Hayashida Tetsu, Aiura Kouichi, Itou Yasuhiro, Hashimoto Takeo, Kawachi Shigeyuki, Tanabe Minoru, Wakabayashi Gou, Shimazu Motohide, Ueda Masakazu, Kitajima Masaki

    第64回日本臨床外科学会総会, 

    2002.11
    , 

    Oral presentation (general)

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • BRCA2変異片アレル導入細胞株を用いたゲノム不安定性と発癌メカニズムの検証

    2024.04
    -
    2027.03

    基盤研究(C), Principal investigator

  • 人工知能による乳房超音波診断支援システムの精度向上と実用化の検討

    2020.04
    -
    2023.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

  • HOXB9 expression in breast cancer predicts efficacy of bevacizumab treatment

    2014.04
    -
    2017.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research (C), Principal investigator

    　View Summary

    Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as a strong angiogenic factor in breast cancer progresson. This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis. Bevacizumab, an anti-VEGF antibody, remarkably suppressed tumor proliferation by inhibiting angiogenesis in HOXB9-overexpressing xenografts. HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation through microenvironmental communication via IL6 signaling; moreover, silencing of VEGF or IL6 terminates microenvironmental crosstalk. Thus, HOXB9 and IL6 may be surrogate markers for bevacizumab treatment in breast cancer.

Page Top ▲

Awards 【 Display / hide 】

  • The 8th International Symposium On Cancer Research and Therapy, Subsidy Award

    2013.11

  • 第51回日本癌治療学会　最優秀演題賞

    2013.10, 日本癌治療学会

  • 第22回広島がんセミナー　最優秀演題賞

    2011.10

  • 第19回日本がん転移学会学術総会　最優秀演題賞

    2011.06, 日本がん転移学会

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • LECTURE SERIES, SURGERY

    2025

  • LECTURE SERIES, SURGERY

    2024

  • LECTURE SERIES, SURGERY

    2023

  • LECTURE SERIES, SURGERY

    2022

  • LECTURE SERIES, SURGERY

    2021

display all >>

Page Top ▲